Cargando…

Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma

The efficacy of sequential everolimus, an orally administered inhibitor of mammalian target of rapamycin (mTOR), was proven in a placebo-controlled phase III study, where median progression-free survival was 4.9 vs 1.9 months for placebo (hazard ratio: 0.33, P < 0.001). Placebo crossovers (80%) c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Maxine, Abdollah, Firas, Schmitges, Jan, Jeldres, Claudio, Shariat, Shahrokh F, Perrotte, Paul, Karakiewicz, Pierre I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818936/ https://www.ncbi.nlm.nih.gov/pubmed/24198635 http://dx.doi.org/10.2147/OAJU.S13283

Ejemplares similares

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

The Role of Everolimus in Renal Cell Carcinoma
por: Meskawi, Malek, et al.
Publicado: (2015)

Primary lymphomas of the genitourinary tract: A population-based study
por: Palumbo, Carlotta, et al.
Publicado: (2020)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
por: Shahani, Rohan, et al.
Publicado: (2010)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature
por: Mbeutcha, Aurélie, et al.
Publicado: (2016)

Role of lymphadenectomy during primary surgery for kidney cancer
por: Bekku, Kensuke, et al.
Publicado: (2023)

Everolimus – a new approach in the treatment of renal cell carcinoma
por: Anandappa, G, et al.
Publicado: (2010)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Everolimus‐induced gastric antral vascular ectasia in advanced renal cancer
por: Hata, Kenichi, et al.
Publicado: (2020)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
por: Tan, Xiaojie, et al.
Publicado: (2015)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta‐analyses
por: Mostafaei, Hadi, et al.
Publicado: (2021)

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?
por: Pantano, Francesco, et al.
Publicado: (2015)

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
por: Vartolomei, Liliana, et al.
Publicado: (2022)

SAT-169 Adrenocortical Cancer Is Diagnosed at Large Size and Advanced Stage in a Canadian Referral Center; Focus on Modes of Presentation Depending on Stages
por: Poirier, Jonathan, et al.
Publicado: (2020)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma
por: Piccinelli, Mattia Luca, et al.
Publicado: (2023)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
por: Guo, Gang, et al.
Publicado: (2021)

Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review
por: Aydh, Abdulmajeed, et al.
Publicado: (2020)

Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
por: Schmidinger, Manuela, et al.
Publicado: (2022)

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qe0qkmrlje6odosv6s03b4qj1m